← Eichor
Condition: Metastatic Sarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcom
Phase 1/Phase 2 · 6 location(s) · GlaxoSmithKline · NCT07602777Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatm
NA · 11 location(s) · Centre Oscar Lambret · NCT06211257IVIM & OLINK in Sarcoma
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT05950594Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Phase 1 · 1 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06235125A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 2/Phase 3 · 202 location(s) · National Cancer Institute (NCI) · NCT05691478VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07028086Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07066982Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Vebreltinib for Advanced or Metastatic CCS
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07153887Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04199026A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07479732Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Phase 1/Phase 2 · 8 location(s) · Adcendo ApS · NCT06797999A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05542407PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06074692Musculoskeletal Cancers Remote Monitoring and Care
NA · 1 location(s) · Case Comprehensive Cancer Center · NCT07129226A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Phase 2 · 2 location(s) · British Columbia Cancer Agency · NCT04273061A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiot
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06114225A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.